GILD Company Profile and Key Details

Gilead Sciences, Inc. (NASDAQ:GILD) closed at $124.16 USD, losing -$0.13 (-0.10%) from the previous close of $124.29. The stock is currently within 5% of its 52-week high $88.57 and $128.70. With a market capitalization of about $154.04 billion, Gilead Sciences, Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 7.54 million shares, in line with its 52-week average. Headquartered in Foster City, CA, Gilead Sciences, Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Daniel O'Day, the company employs approximately 17,600 people and listed since January 22, 1992. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD has shown sold momentum, gaining 3.12% over the past week and 10.37% over the past quarter, though year-to-date performance is up 34.42%. Short-term trend indicators are bearishly aligned (SMA20 1.02%, SMA50 1.53%, SMA200 9.51%). The stock’s 14-day RSI is 54.78 (neutral), while the ATR of 3.01 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -3.53% below its high and over 40.18% above its low. Average 10-day trading volume of 9.65 million shares is slightly above the 3-month average of 7.36 million, indicating heightened recent market interest.

Gilead Sciences, Inc. last paid a dividend of 3.16 per share, this equals a trailing yield of roughly 3.69%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $270.99. This means the shares are trading below this model’s fair value.

Gilead Sciences, Inc. has 1.24 billion shares outstanding. The public float is 1.24 billion shares, elevated short interest at 1.61% of float. This equals 19.99 million shares. The short ratio is 3.54 days. Institutional investors hold 90.83% of the float. Insiders own 0.1%. GILEAD SCIENCES, INC. holds 14.82 million shares, GILEAD SCIENCES INC has 13.91 million shares and MARTIN JOHN C has 2.88 million shares. Over the past six months, insider transactions show net selling. They sold 76.00 thousand shares across 23 transactions.

Gilead Sciences, Inc. generated EPS of $6.46 over the past year. Five-year average earnings growth is -38.13%. Wall Street analysts project EPS growth of 26.27% annually over the next five years. The latest quarter delivered EPS of $2.47. The next quarter is forecast at $1.86. Next year's EPS is expected at $7.59. Analyst sentiment is bullish. Analyst rating data shows there are 17 Strong Buy ratings, 10 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $151.00 to $84.00. The high target offers 21.62% upside. The low target suggests -32.35% downside. The mean target is $126.00. This offers 1.48% upside. Gilead Sciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 30, 2025, missed forecasts by 15.96%. The prior quarter beat by 2.55%. Over the last six quarters, Apple has recorded several small beats. These include 24.84% in August 08, 2024.

Gilead Sciences, Inc. trades at a P/E ratio of 19.0, slightly below the S&P 500 average, with a price-to-sales ratio of 5.29 and a price-to-book ratio of 7.18 trading at moderately above to book value. The P/FCF stands at 16.15, also below market averages.

Our AI price prediction model suggests that Gilead Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.58%, with price expected at $119.72 by January 02, 2026, within a range of $117.77 to $121.58 3-Month Outlook: Projected rise of 7.53%, reaching $133.51 by March 19, 2026, with a range of $129.89 to $136.51. 1-Year Outlook: Projected gain of 11.16%, with price at $138.02 by December 18, 2026, within a range of $133.90 to $142.57.

Gilead Sciences, Inc. (NASDAQ:GILD) shares are up 34.42% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Gilead Sciences, Inc. trading at a premium to the broader market with a P/E of 19.0. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $97.94, suggesting -21.12% downside. Our AI forecast model points to short-term weakness (-3.58% over two weeks), a medium-term rise (7.53% over three months), and a longer-term gain (11.16% over one year), with expected trading ranges indicating moderate volatility.